This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Vital Signs - The Analyst's Perspective - March 2015 Issue
Vital Signs - The Analyst's Perspective - March 2015 Issue
RELEASE DATE
07-Apr-2015
07-Apr-2015
REGION
North America
North America
Deliverable Type
Market Research
Market Research
Research Code: 9A35-00-32-00-00
SKU: HC02612-NA-MR_16734
$500.00
In stock
SKU
HC02612-NA-MR_16734
Description
This issue of Vital Signs, released on April 3, 2015, discusses next-generation sequencing bioinformatics partnerships, FDA approval of Novartis's ZARXIO, 23andMe's foray into drug development, and Johnson & Johnson's sale of Cordis to Cardinal Health.
Table of Contents
This week's issue
Popular Topics
This market insight provides an analysis of the regulatory trends occurring in the US pharma/biotech industry for 2014. Included in this deliverable is an analysis of the new molecular entities (NME) approved by the US Food and Drug Administration in 2014 and predictions for 2015. Trends are showing that the US Food and Drug Administration is moving towards greater efficiency and expedited review periods, which will lead to faster access to care.
| Deliverable Types | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Christi Bird |
| Industries | Healthcare |
| WIP Number | 9A35-00-32-00-00 |
| Is Prebook | No |